Investigators performed a retrospective cohort review of patients with Type 2 diabetes mellitus (T2DM) who underwent primary, elective posterior lumbar fusion. The study team identified chronic preoperative use of GLP-1 receptor agonist therapy and extracted demographic and surgical details through manual chart review. The report defined return of postoperative bowel function as either flatulence or a bowel movement and listed that as a primary outcome alongside surgical complications and wound healing. Patient-reported outcome measures (PROMs) were included as secondary endpoints. The source did not report specifics on dosing, duration thresholds for “chronic” therapy, or perioperative medication management protocols.
The cohort included 57 patients with preoperative GLP-1 agonist use and 60 patients without. The study team observed an earlier mean time to return of bowel function in the GLP-1 group: 1.35 ± 1.30 days versus 1.90 ± 0.77 days in controls (P = 0.013). That difference was described in absolute mean days, and the investigators reported it as statistically significant. Short, clinically relevant signal: patients on GLP-1 therapy experienced bowel recovery roughly half a day sooner on average. The article did not provide granular timing distributions beyond mean and standard deviation values.
Authors noted no between-group differences in discharge disposition or length of stay. Inpatient complication rates and postoperative wound abnormalities were also similar across groups. Patient-reported outcomes measures, captured as secondary outcomes, did not differ between patients taking GLP-1 agonists and those who were not. In sum, chronic preoperative GLP-1 receptor agonist use was not associated with inferior short-term surgical outcomes or with worse PROMs according to the data presented.
A Poisson regression model predicting the postoperative day of bowel function return was performed. The regression analysis showed that GLP-1 agonist use independently decreased time to bowel recovery, with a reported rate ratio of 0.69 (P = 0.028). Investigators therefore concluded the association persisted after adjustment in the selected multivariable framework described in the abstract. The source abstract did not list the full set of covariates included in the model within the abstract text; the reader would need to consult the full text for model specification and sensitivity checks.
The authors offered two mechanistic possibilities consistent with the observed association: chronic adaptations in gut motility among patients on GLP-1 therapy, and anti-inflammatory properties of GLP-1 receptor agonists that might favor earlier functional recovery. Those mechanistic ideas were presented as hypotheses; the abstract explicitly stated that further study is required to test them. No experimental physiologic data or direct measures of inflammation or motility were reported in the abstract.
The report is a retrospective cohort, and the study design imposes the usual limits on causal inference. The abstract acknowledged the need for additional research to corroborate findings and to explore mechanisms. Important methodological details were not reported in the abstract: the exact covariates in the Poisson model, thresholds or definitions for chronic GLP-1 exposure, dosing regimens, timing of the last preoperative dose, and any perioperative GLP-1 management strategy. The sample sizes for each group were provided (57 and 60 patients), but the abstract did not report power calculations or whether the study was powered for secondary endpoints such as PROMs. Future work should clarify whether the bowel-motility effect translates into measurable clinical benefits beyond an earlier passage of flatus or stool, identify biologic mediators, and determine whether findings replicate in prospective or randomized settings. The authors called explicitly for further study to confirm the association and to define its clinical implications.